UNSPSC 51282323: Erythromycin oxime

This classification denotes a macrolide antibiotic C37H68N2O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10W452CMTZ, chemically known as erythromycin, 9-oxime, but more generally known as erythromycin oxime, which bears US NIH Compound Identifier 6537896. Most nations, for tariff and trade purposes, schedule erythromycin oxime under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN OXIME remains US FDA's Preferred Term for this commodity.

Erythromycin oxime bears US NLM identifiers UMLS ID C0207096 and NCI Concept Code C87758. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=NO)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.

UNSPSC 51282323 Erythromycin oxime is a Commodity code that classifies a specific pharmaceutical active ingredient, but state and local governments' actual purchasing activity under this code shows limited direct procurement aligned with the nominal product scope. The recent opportunities on file involve broader pharmaceutical procurement — principally antibiotic and emergency-response medications supplied through warehouse and piggyback contracts — rather than erythromycin oxime specifically. Issuing bodies include state departments of health and county health authorities managing pharmaceutical inventory for public health initiatives, emergency preparedness, and community health programs. These entities typically procure through competitive bidding processes (IFB and ITB notices) that leverage cooperative purchasing vehicles such as MMCAP and multiagency consortia to consolidate demand and reduce per-unit costs.

Activity is concentrated in Illinois and Florida based on recent postings. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026 (Solicitation 26482DPHPREPDB53392, IFB process) for Doxycycline Hyclate and Ciprofloxacin Hydrochloride with a 12-month initial term and renewal options. Seminole County, Florida released an IFB on June 30, 2026 (IFB60459723LAS, response deadline July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the county community health building. The Seminole County procurement highlighted federal compliance requirements linked to potential FEMA funding and required vendors to meet E-Verify and drug-free workplace certification standards. The code shows sparse direct activity for erythromycin oxime itself; procurement under this code appears to be episodic and embedded within larger pharmaceutical supply agreements rather than standalone line-item purchases.